Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Atazanavir 300 mg Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

NCT02603107
View directory record Official record
Conditions
HIV-1 Infection
Interventions
RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
63
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 17, 2026, 2:56 PM EDT
Terminated Phase 2 Interventional Results available

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

NCT02386098
View directory record Official record
Conditions
HIV Infections
Interventions
BMS-955176, Atazanavir (ATV), Ritonavir (RTV), Dolutegravir (DTG), Tenofovir (TDF)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Beverly Hills, California • Los Angeles, California • Palm Springs, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

NCT01903031
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Nuvaring, EFV, ATV/r, TDF, NRTIs
Device · Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01475838
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
PI, RTV, FTC/TDF, Stribild
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Beverly Hills, California • Hayward, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

NCT00225017
View directory record Official record
Conditions
HIV Infection, Hyperlipidemia
Interventions
Atazanavir, current antiretroviral regimen
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 17, 2026, 2:56 PM EDT
Completed No phase listed Observational

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

NCT00977756
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir (RAL), Atazanavir (ATV), Ritonavir (RTV), Tenofovir (TDF), Etravirine (ETV), Darunavir (DRV), Maraviroc (MVC), Lopinavir/ritonavir (LPV/r)
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 21 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
33
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

NCT01705574
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
41
States / cities
Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

NCT01384734
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
13
States / cities
San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Results available

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

NCT01691794
View directory record Official record
Conditions
HIV, Pediatric
Interventions
Atazanavir, Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Phoenix, Arizona • Atlanta, Georgia • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 3 Interventional

Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia

NCT00160329
View directory record Official record
Conditions
Hyperlipidemia, HIV Infections
Interventions
Atazanavir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT01106586
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Stribild, ATV, Ritonavir, FTC/TDF, Stribild Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
86
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Results available

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

NCT00762892
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and truvada, Atazanavir, Norvir and Truvada
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

NCT00814879
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
Interventions
Raltegravir, Atazanavir, Standard treatment regimen
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Waterbury, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Interaction Study

NCT00646776
View directory record Official record
Conditions
Antivirals/HIV
Interventions
Rifabutin, Rifabutin + Atazanavir + Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 17, 2026, 2:56 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 1 Interventional

Interaction With HIV Antiretroviral Agents

NCT02556268
View directory record Official record
Conditions
HIV-DDI
Interventions
Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

NCT04021290
View directory record Official record
Conditions
HIV Infections
Interventions
DTG/3TC FDC, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With Proton Pump Inhibitor

NCT00357240
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Atazanavir/Ritonavir, Atazanavir/Ritonavir+Omeprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

NCT00827112
View directory record Official record
Conditions
Human Immunodeficiency Virus-1
Interventions
maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Norwalk, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Sep 17, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

NCT00272779
View directory record Official record
Conditions
HIV Infections
Interventions
ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet, LPV
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Phoenix, Arizona • Laguna Beach, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Sep 17, 2026, 2:56 PM EDT
Terminated No phase listed Observational Results available

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 2:56 PM EDT